Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials.
Zachary W VeitchDaniel ShepshelovichChristina GallagherLisa WangAlbiruni R Abdul RazakAnna SpreaficoPhilippe L BedardLillian L SiuLori M MinasianAaron Richard HansenPublished in: Journal of the National Cancer Institute (2022)
Poor to moderate patient-clinician agreement for symptomatic AEs suggests clinician underreporting in phase I trials. Analyses of severity and interference PRO categories are ongoing.